Salivary immunosuppressive cytokines IL-10 and IL-13 are significantly elevated in oral squamous cell carcinoma patients

Cancer Investigation

Volumn 33, Issue 7, 2015, Pages 318-328

  Aziz, Salman ^a,b   Ahmed, Syed Shoaib ^c   Ali, Asad ^c   Khan, Faiza Akhter ^c   Zulfiqar, Gulraiz ^d   Iqbal, Javed ^c   Khan, Ayyaz Ali ^e   Shoaib, Muhammad ^c  

^a JOUF UNIVERSITY   (Saudi Arabia)

^b Department of Anatomy   (Pakistan)

^c UNIVERSITY OF LAHORE   (Pakistan)

^d KING EDWARD MEDICAL UNIVERSITY   (Pakistan)

^e Federal Postgraduate Medical Institute   (Pakistan)

Author keywords

Cytokines; Interleukin 1 receptor antagonist; Interleukin 10; Interleukin 13; Interleukin 4; Salivary proteins; Squamous cell carcinoma of head and neck

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; SALIVA PROTEIN; IL10 PROTEIN, HUMAN; IL1RN PROTEIN, HUMAN; IL4 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; FEMALE; HUMAN; IMMUNOASSAY; MALE; MIDDLE AGED; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; SALIVA LEVEL; SMOKELESS TOBACCO; SMOKING; TUMOR DIFFERENTIATION; METABOLISM; MOUTH TUMOR; PATHOLOGY; PILOT STUDY; PROGNOSIS; SALIVA; SQUAMOUS CELL CARCINOMA; UPREGULATION;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-10; INTERLEUKIN-13; INTERLEUKIN-4; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PILOT PROJECTS; PROGNOSIS; SALIVA; UP-REGULATION;

EID: 84945122000     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2015.1041642     Document Type: Article

References (58)

1. Elledge ROC, Khazaee-Farid R, Walker RJ, Sundaram K, Monaghan A. A library-based ecological study to investigate the contribution of ethnicity to the incidence of oral cancer within health authorities in England and Wales. Br J Oral Maxillofac Surg 2011;49(1): 42-46.
2. de Camargo Cancela M, Voti L, Guerra-Yi M, Chapuis F, Mazuir M, Curado MP. Oral cavity cancer in developed and in developing countries: Population-based incidence. Head Neck 2010;32(3): 357-367.
3. Jemal A, Bray F, Center MM, Ferlay J,Ward E, FormanD.Global cancer statistics. CA Cancer J Clin 2011;61(2): 69-90.
4. Warnakulasuriya S. Living with oral cancer: Epidemiology with particular reference to prevalence and life-style changes that influence survival. Oral Oncol 2010;46(6): 407-410.
5. Negus R, Balkwill F. Cytokines in tumour growth, migration and metastasis.World J Urol 1996;14(3): 157-165.
6. Ben-Baruch A. Inflammation-associated immune suppression in cancer: The roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 2006;16(1): 38-52.
7. Dunlop RJ, Campbell CW. Cytokines and advanced cancer. J Pain Symptom Manage 2000;20(3): 214-232.
8. Terabe M, Park JM, Berzofsky JA. Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother 2004;53(2): 79-85.
9. Fallon PG, Jolin HE, Smith P, Emson CL, TownsendMJ, Fallon R, Smith P,McKenzie AN. IL-4 induces characteristicTh2 responses even in the combined absence of IL-5, IL-9, and IL-13. Immunity 2002;17(1): 7-17.
10. Jager A, Sleijfer S, van der Rijt CCD. The pathogenesis of cancer related fatigue: Could increased activity of proinflammatory cytokines be the common denominator? Eur J Cancer 2008;44(2): 175-181.
11. Chen Z,Malhotra PS,Thomas GR, Ondrey FG, Duffey DC, Smith CW, Enamorado I, Yeh NT, Kroog GS, Rudy S, McCullagh L, Mousa S, Quezado M, Herscher LL, Van Waes C . Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999;5(6): 1369-1379.
12. Hazelbag S, Fleuren GJ, Baelde JJ, Schuuring E, Kenter GG, Gorter A. Cytokine profile of cervical cancer cells. Gynecol Oncol 2001;83(2): 235-243.
13. Azizi G, Mirshafiey A. The potential role of proinflammatory and antiinflammatory cytokines in Alzheimer disease pathogenesis. Immunopharmacol Immunotoxicol 2012;34(6): 881-895.
14. Vezzani A, Moneta D, Richichi C, Aliprandi M, Burrows SJ, Ravizza T, Perego C, De SimoniMD. Functional role of inflammatory cytokines and antiinflammatorymolecules in seizures and epileptogenesis. Epilepsia 2002;43(s5): 30-35.
15. Khandavilli SD, Ceallaigh PO, Lloyd CJ, Whitaker R. Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol 2009;45(10): 912-914.
16. Czerninski R, Basile J, Kartin-Gabay T, Laviv A, Barak V. Cytokines and tumor markers in potentially malignant disorders and oral squamous cell carcinoma: A pilot study. Oral Dis 2014;20(5): 477-481.
17. Chang K-P, Wu C-C, Fang K-H, Tsai C-Y, Chang Y-L, Liu SC, Kao H-K. Serum levels of chemokine (C-X-C motif) ligand 9 (CXCL9) are associated with tumor progression and treatment outcome in patients with oral cavity squamous cell carcinoma. Oral Oncol 2013;49(8): 802-807.
18. Elashoff D, Zhou H, Reiss J, Wang J, Xiao H, Henson B, Hu S, Arellano M, Sinha U, Le A,Messadi D,Wang M, Nabili V, Lingen M,Morris D, Randolph T, Feng Z, Akin D, KastratovicDA, Chia D, Abemayor E, Wong DT. Prevalidation of salivary biomarkers for oral cancer detection. Cancer Epidemiol Biomarkers Prev 2012;21(4): 664-672.
19. Arellano-Garcia ME, Hu S, Wang J, Henson B, Zhou H, Chia D, Wong DT. Multiplexed immunobead-based assay for detection of oral cancer protein biomarkers in saliva. Oral Dis 2008;14(8): 705-712.
20. Korostoff A, Reder L,Masood R, SinhaUK.Therole of salivary cytokine biomarkers in tongue cancer invasion and mortality. Oral Oncol 2011;47(4): 282-287.
21. Liu J,Duan Y. Saliva: A potential media for disease diagnostics and monitoring. Oral Oncol 2012;48(7): 569-577.
22. Pindborg JJ, Reichart P, Smith C, van derWaal I. Definitions and explanatory notes. InHistological Typing of Cancer and Precancer of the Oral Mucosa. Berlin: Springer, 1997, 11-31.
23. Costa NL, Valadares MC, Souza PPC, Mendonça EF, Oliveira JC, Silva TA, Batista AC. Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma. Oral Oncol 2013;49(3): 216-223.
24. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57(3): 503-512.
25. Volpert OV, Fong T, Koch AE, Peterson JD,Waltenbaugh C, Tepper RI, Bouck NP. Inhibition of angiogenesis by interleukin 4. J Exp Med 1998;188(6): 1039-1046.
26. Conticello C, Pedini F, Zeuner A, Patti M, Zerilli M, Stassi G, Messina A, PeschleC,DeMaria R. IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol 2004;172(9): 5467-5477.
27. Ma HL, Whitters MJ, Jacobson BA, Donaldson DD, Collins M, Dunussi-Joannopoulos K. Tumor cells secreting IL-13 but not IL-13Ralpha2 fusion protein have reduced tumorigenicity in vivo. Int Immunol 2004;16(7): 1009-1017.
28. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA. NKT cellmediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000;1(6): 515-520.
29. Kaskas NM, Moore-Medlin T, McClure GB, Ekshyyan O, Vanchiere JA, Nathan CA. Serum biomarkers in head and neck squamous cell cancer. JAMA Otolaryngology-Head Neck Sur 2014;140(1): 5-11.
30. Hamzavi M, Tadbir AA, Rezvani G, Ashraf MJ, Fattahi MJ, Khademi B, Sardari Y, Jeirudi N. Tissue expression, serum and salivary levels of IL-10 in patients with head and neck squamous cell carcinoma. Asian Pac J Cancer Prev 2013;14(3): 1681-1685.
31. Woodford D, Johnson SD, De Costa AM, Young MR. An inflammatory cytokine milieu is prominent in premalignant oral lesions, but subsides when lesions progress to squamous cell carcinoma. J Clin Cell Immunol 2014;5(3).
32. Formentini A, Prokopchuk O, Strater J, Kleeff J, Grochola LF, Leder G, Henne-Bruns D, Korc M, Kornmann M. Interleukin-13 exerts autocrine growth-promoting effects on human pancreatic cancer, and its expression correlates with a propensity for lymph node metastases. Int J Colorectal Dis 2009;24(1): 57-67.
33. Prokopchuk O, Liu Y, Henne-Bruns D, Kornmann M. Interleukin-4 enhances proliferation of human pancreatic cancer cells: Evidence for autocrine and paracrine actions. Br J Cancer 2005;92(5): 921-928.
34. Kanai T, Watanabe M, Hayashi A, Nakazawa A, Yajima T, Okazawa A, Yamazaki M, Ishii H, Hibi T. Regulatory effect of interleukin-4 and interleukin-13 on colon cancer cell adhesion. Br J Cancer 2000;82(10): 1717-1723.
35. ChenCJ, SungWW, SuTC, ChenMK,WuPR, YehKT, Ko JL, Lee H.High expression of interleukin 10might predict poor prognosis in early stage oral squamous cell carcinoma patients. Clin Chim Acta 2013;415: 25-30.
36. Chuang CY, Sung WW, Wang L, Lin WL, Yeh KT, Su MC, Hsin CH, Lee SY, Wu BC, Cheng YW, Lee H. Differential impact of IL-10 expression on survival and relapse between HPV16-positive and -negative oral squamous cell carcinomas. PLoS One 2012;7(10): E47541.
37. Alhamarneh O, Agada F, Madden L, Stafford N, Greenman J. Serum IL10 and circulating CD4(+) CD25(high) regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma. Head Neck 2011;33(3): 415-423.
38. Vairaktaris E, Yapijakis C, Serefoglou Z, AvgoustidisD, Critselis E, Spyridonidou S, Vylliotis A, Derka S, Vassiliou S, Nkenke E, Patsouris E. Gene expression polymorphisms of interleukins-1 beta, -4, -6, -8, -10, and tumor necrosis factors-alpha, -beta: Regression analysis of their effect upon oral squamous cell carcinoma. J Cancer Res Clin Oncol 2008;134(8): 821-832.
39. Vairaktaris E, Yapijakis C, Serefoglou Z, Derka S, Vassiliou S, Nkenke E, Vylliotis A, Spyridonidou S, Neukam SW, Schlegel KA, Patsouris E. The interleukin-10 (-1082A/G) polymorphism is strongly associated with increased risk for oral squamous cell carcinoma. Anticancer Res 2008;28(1A): 309-314.
40. ArendWP. Interleukin-1 receptor antagonist: Discovery, structure and properties. Prog Growth Factor Res 1990;2(4): 193-205.
41. Dubost JJ, Perrier S, Afane M, Viallard JL, Roux-Lombard P, Baudet-Pommel M, Begue C, Kemeny JL, Sauvezie B. IL-1 receptor antagonist in saliva; characterization in normal saliva and reduced concentration in Sjo. . gren's syndrome (SS). Clin Exp Immunol 1996;106(2): 237-242.
42. Linkov F, Lisovich A, Yurkovetsky Z, Marrangoni A, Velikokhatnaya L, Nolen B, Winans M, Bigbee W, Siegfried J, Lokshin A, Ferris RL. Early detection of head and neck cancer: Development of a novel screening tool using multiplexed immunobeadbased biomarker profiling. Cancer Epidemiol Biomarkers Prev 2007;16(1): 102-107.
43. Singer CF, Kronsteiner N, Marton E, Walter I, Kubista M, Czerwenka K, Schreiber M, Tschugguel W, Wieser F, Kubista E. Interleukin-1 system and sex steroid receptor gene expression in human endometrial cancer. Gynecol Oncol 2002;85(3): 423-430.
44. Van Le L, Haskill S, Jaffe GJ, Fowler WC, Jr. Expression of interleukin-1 and interleukin-1 receptor antagonists in endometrial cancer. Gynecol Oncol 1991;42(2): 161-164.
45. Smith DR, Kunkel SL, Standiford TJ, Chensue SW, Rolfe MW, Orringer MB, Whyte RI, Burdick MD, Danforth JM, Gilbert AR, Strieter RM. The production of interleukin-1 receptor antagonist by human bronchogenic carcinoma. Am J Pathol 1993;143(3): 794-803.
46. Oelmann E, Kraemer A, Serve H, Reufi B, Oberberg D, Patt S, Herbst H, Stein H, Thiel E, Berdel WE. Autocrine interleukin-1 receptor antagonist can support malignant growth of glioblastoma by blocking growth-inhibiting autocrine loop of interleukin-1. Int J Cancer 1997;71(6): 1066-1076.
47. Iizuka N, Hazama S, Hirose K, Abe T, Tokuda N, Fukumoto T, Tangoku A, Oka M. Interleukin-1 receptor antagonist mRNA expression and the progression of gastric carcinoma. Cancer Lett 1999;142(2): 179-184.
48. Fujiwaki R, Hata T, Miyazaki K, Kawamura T, Inada K. Elevation of serum interleukin-1 receptor antagonist levels in women with gynaecological cancers. Br J Obstet Gynaecol 1997;104(12): 1407-1408.
49. Fujiwaki R, Iida K, Nakayama K, Kanasaki H, Hata K, Katabuchi H,Okamura H, Miyazaki K. Clinical significance of interleukin-1 receptor antagonist in patients with cervical carcinoma. Gynecol Oncol 2003;89(1): 77-83.
50. Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: Correlations with local tumor extent and prognosis. J Surg Oncol 2003;84(3): 151-159.
51. Graziano F, Ruzzo A, Canestrari E, Loupakis F, Santini D, Rulli E, Humar B,GalluccioN, Bisonni R, Floriani I,Maltese P, Falcone A, Tonini G, Catalano V, Fontana A, Giustini L, Masi G, Vincenzi B, Alessandroni P,MagnaniM.Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. Pharmacogenomics J 2009;9(1): 78-84.
52. Mustea A, Pirvulescu C, Konsgen D, Braicu EI, Yuan S, Sun P, Lichtenegger W, Sehouli J. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Cytokine 2008;42(1): 77-84.
53. Rathakrishnan A, Wang SM, Hu Y, Khan AM, Ponnampalavanar S, Lum LC, Manikam R, Sekaran SD. Cytokine expression profile of dengue patients at different phases of illness. PLoS One 2012;7(12): E52215.
54. Bomert M, Kollisch G, Roponen M, Lauener R, Renz H, Pfefferle PI, Al-Fakhri N. Analytical performance of a multiplexed, beadbased cytokine detection system in small volume samples. Clin Chem Lab Med 2011;49(10): 1691-1693.
55. de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 2003;10(1): 133-139.
56. Zhang X, Junior CR, Liu M, Li F, D'Silva NJ, Kirkwood KL. Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss. Oral Oncol 2013;49(2): 119-128.
57. Pries R, Wollenberg B. Cytokines in head and neck cancer. Cytokine Growth Factor Rev 2006;17(3): 141-146.
58. Schapher M, Wendler O, Groschl M. Salivary cytokines in cell proliferation and cancer. Clin Chim Acta 2011;412 (19-20): 1740-1748.